WOMEN with advanced breast cancer could have access to treatment to help prolong their life.
The National Institute for Health and Care Excellence (Nice) has recommended the use of Kisqali, also known as ribociclib, for postmenopausal women with HR+/HER2-locally advanced or metastatic breast cancer.
The drug by Novartis, which received authorisation by the European Commission earlier this year, has been welcomed by clinicians.
Maria Noblet, consultant nurse in the breast unit at Cosham’s Queen Alexandra Hospital, said: ‘I was delighted we now have another tool in our toolbox to treat women with breast cancer.
‘It is one of the newer biological compounds we have to treat breast cancer and it is useful to have to offer women.’
Around 55,000 women in the UK are diagnosed with breast cancer each year. One-third will develop advanced diseases.
Maria added: ‘The bottom line is this is a beneficial treatment that will allow women, with these particular parameters, to live longer without getting any worse.
‘It will allow people to have a life living and not thinking about dying.’
The Nice recommendation has been published in its final draft guidance. Novartis is awaiting Nice Technology Appraisal Guidance, the final step of the approval process.